Daniel Cressy, a 23-year-old from Metairie, Louisiana, has been declared functionally cured of sickle cell disease after completing a gene-editing treatment at Manning Family Children’s Hospital in New Orleans.
The hospital has described Cressy as the first person from the US Gulf Coast region to complete treatment using Casgevy’s CRISPR/Cas9 technology and reach that functional-cure milestone. The June 22 bell-ringing ceremony marked the end of a long treatment process and the beginning of what Cressy has called his next phase of life.
For Cressy, the result is more than a medical milestone. He has tied the treatment to a long-running goal of becoming a commercial pilot, a career path complicated by his sickle cell diagnosis and the medical risks associated with the disease.
A Gene-Editing Treatment With Personal Stakes
Sickle cell disease is an inherited blood disorder that can cause severe pain episodes, organ damage, frequent hospitalizations, and other serious complications. It disproportionately affects Black patients in the US, and Louisiana has been described by Manning Family Children’s Hospital as having one of the country’s highest per-capita burdens of the disease.
Cressy was diagnosed in infancy. He grew up wanting to fly commercial aircraft, but his medical condition created a barrier to that ambition. The hospital and Cressy have said he pursued gene-editing therapy after learning that curing the disease could reopen a path toward aviation licensing.
Casgevy is part of a new generation of treatments that use CRISPR-based editing to alter a patient’s own stem cells. The treatment is not a simple injection. It requires collecting a patient’s cells, modifying them, preparing the body with chemotherapy, and then infusing the edited cells back into the patient.
Manning Family Children’s Hospital has said Cressy’s treatment process stretched across roughly two years. His cells were collected, sent for genetic modification, returned to New Orleans, and then reinfused after chemotherapy. Cressy spent about a month in inpatient recovery and monitoring before the hospital marked the treatment as complete.
Why The Milestone Matters
The case lands at the intersection of medical technology and access. Gene-editing therapies have moved from research breakthrough to real-world treatment, but they remain complex, expensive, and logistically demanding. For patients with sickle cell disease, that means the promise is enormous while the practical hurdles are still very real.
That tension is especially visible in Louisiana, where sickle cell disease is a significant public health issue. A successful functional cure in New Orleans does not make the treatment easy to obtain for everyone who might benefit from it, but it does show that advanced cell and gene therapies are beginning to reach patients outside the largest coastal research hubs.
The hospital credited Cressy’s care team, including Dr. Ben Watkins, director of its stem cell transplant and cellular therapies program, for guiding the treatment. Hospital CEO Lucio Fragoso framed the result as a sign of what curative gene therapy could make possible for more families.
Cressy has spoken about using the experience to build a broader mission around aviation, medical access, and opportunity. He has discussed work on a book titled Blessing in the Skies and a nonprofit called the Privileged Pilots Project, focused on expanding access to care, aviation, and support for people facing medical, economic, or social barriers.
For now, the most immediate change is personal: a young patient who spent his life with a disease that shaped his choices has been told he is functionally cured. The next test will be how far that result can travel beyond one hospital room, one ceremony, and one patient’s unusually visible dream of flight.